Search Results

RNAimmune, Inc., a partner of Innoforce, announced the U.S. Food and Drug Administration (FDA) granted IND clearance for its RV-1770 Respiratory Syncytial Virus (RSV) mRNA vaccine.

RNAimmune, Inc. announced today that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR Annual Meeting 2023.

RNAimmune, Inc. (the “Company” or “RNAimmune”) today announced that the Company has received a clearance from the United States Food & Drug Administration (FDA) cleared its Investigational New Drug (IND) application a Phase I clinical trial for RV-1730, a SARS-CoV-2 vaccine booster candidate.

RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing.

RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an investigational new drug.

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announces today completion of its $2.35 million seed round financing from multiple venture capitalists including Terra Magnum Capital Partners. The Company will use the proceeds to advance its Covid-19

Sirnaomics, Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, today announced a corporate technology spinoff establishing an independent biopharmaceutical company, RNAimmune, Inc. This new entity is focusing on and specializing in messenger RNA (mRNA) based therapeutics and vac

Sirnaomics Ltd., a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has announced its interim results for the six months ended 30 June 2023.